Roche Holding AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Phase 3
Completed
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2007-11-12
- Last Posted Date
- 2015-02-23
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 424
- Registration Number
- NCT00556322
A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Phase 3
Completed
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Drug: erlotinib [Tarceva]Drug: Placebo
- First Posted Date
- 2007-11-12
- Last Posted Date
- 2015-02-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 889
- Registration Number
- NCT00556712
A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis Who Have Received Previous Bonviva Treatment
Phase 4
Completed
- Conditions
- Post-Menopausal Osteoporosis
- Interventions
- First Posted Date
- 2007-10-30
- Last Posted Date
- 2011-07-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 781
- Registration Number
- NCT00551174
A Study of NeoRecormon (Epoetin Beta), CellCept (Mycophenolate Mofetil) and Prednisone in Patients With Low or Intermediate Myelodysplastic Syndromes.
Phase 2
Completed
- Conditions
- Myelodysplastic Syndromes
- Interventions
- First Posted Date
- 2007-10-30
- Last Posted Date
- 2016-07-25
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 10
- Registration Number
- NCT00551291
A Study of Mircera for the Maintenance Treatment of Participants With Chronic Renal Anemia
Phase 3
Completed
- Conditions
- Chronic Renal Anemia
- Interventions
- First Posted Date
- 2007-10-30
- Last Posted Date
- 2016-03-30
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 208
- Registration Number
- NCT00550680
A Study of Intravenous Mircera for the Correction of Anemia in Dialysis Patients.
Phase 3
Completed
- Conditions
- Anemia
- Interventions
- Drug: methoxy polyethylene glycol-epoetin beta [RO0503821, Mircera]Drug: Epoetin
- First Posted Date
- 2007-10-19
- Last Posted Date
- 2016-09-19
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 80
- Registration Number
- NCT00546481
BONCURE Study: A Study of Monthly Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis on Bisphosphonate Therapy.
- First Posted Date
- 2007-10-17
- Last Posted Date
- 2016-10-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 677
- Registration Number
- NCT00545779
A Study of Bonviva (Ibandronate) Once Monthly in Post-Menopausal Women With Osteopenia.
Phase 3
Completed
- Conditions
- Post-Menopausal Osteopenia
- Interventions
- Drug: ibandronate [Bonviva/Boniva]Drug: Placebo
- First Posted Date
- 2007-10-17
- Last Posted Date
- 2017-01-26
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 150
- Registration Number
- NCT00545207
A Study of Oseltamivir (Tamiflu) for Treatment of Influenza in Immunocompromised Participants.
- First Posted Date
- 2007-10-17
- Last Posted Date
- 2018-07-12
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 228
- Registration Number
- NCT00545532
- Locations
- 🇺🇸
Baylor University Medical Center Transplant Administration, Dallas, Texas, United States
🇺🇸Sammons Cancer Center-Baylor University; Blood & Marrow Transplantation, Dallas, Texas, United States
🇺🇸UCLA Medical center Medicine/Nephrology, Los Angeles, California, United States
A Study of Once Monthly Bonviva (Ibandronate) in Prevention of Glucocorticoid-Induced Osteoporosis.
- First Posted Date
- 2007-10-17
- Last Posted Date
- 2016-05-12
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 140
- Registration Number
- NCT00545051
© Copyright 2025. All Rights Reserved by MedPath